CO2021004681A2 - Uso de reboxetina para el tratamiento de narcolepsia - Google Patents
Uso de reboxetina para el tratamiento de narcolepsiaInfo
- Publication number
- CO2021004681A2 CO2021004681A2 CONC2021/0004681A CO2021004681A CO2021004681A2 CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2 CO 2021004681 A CO2021004681 A CO 2021004681A CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2
- Authority
- CO
- Colombia
- Prior art keywords
- narcolepsy
- reboxetine
- treatment
- cataplexy
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021004681A2 true CO2021004681A2 (es) | 2021-06-21 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0004681A CO2021004681A2 (es) | 2018-10-15 | 2021-04-14 | Uso de reboxetina para el tratamiento de narcolepsia |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (zh) |
| JP (1) | JP2022504975A (zh) |
| KR (2) | KR20240119194A (zh) |
| CN (1) | CN112888430A (zh) |
| AU (2) | AU2019361915A1 (zh) |
| BR (1) | BR112021007019A2 (zh) |
| CA (1) | CA3115983A1 (zh) |
| CL (1) | CL2021000924A1 (zh) |
| CO (1) | CO2021004681A2 (zh) |
| CR (1) | CR20210514A (zh) |
| EC (1) | ECSP21031200A (zh) |
| IL (1) | IL282311A (zh) |
| MX (1) | MX2021004207A (zh) |
| PE (1) | PE20211199A1 (zh) |
| SG (1) | SG11202103588WA (zh) |
| WO (1) | WO2020081461A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| KR20230055668A (ko) * | 2021-10-19 | 2023-04-26 | 단국대학교 천안캠퍼스 산학협력단 | 레복세틴을 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| EP1763354A2 (en) * | 2004-06-09 | 2007-03-21 | Pfizer Limited | Use of reboxetine for the treatment of pain |
| SG11201507121RA (en) * | 2013-03-13 | 2015-10-29 | Aerial Biopharma Llc | Treatment of cataplexy |
-
2019
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/ko active Search and Examination
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/es unknown
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/zh active Pending
- 2019-10-14 CR CR20210514A patent/CR20210514A/es unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/es unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/ko active Application Filing
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/pt unknown
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/ja active Pending
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en unknown
-
2021
- 2021-04-13 IL IL282311A patent/IL282311A/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/es unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/es unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/es unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3866768A4 (en) | 2022-01-05 |
| JP2022504975A (ja) | 2022-01-13 |
| AU2019361915A1 (en) | 2021-05-13 |
| EP3866768A1 (en) | 2021-08-25 |
| CL2021000924A1 (es) | 2021-09-03 |
| CA3115983A1 (en) | 2020-04-23 |
| KR20210071046A (ko) | 2021-06-15 |
| ECSP21031200A (es) | 2021-05-31 |
| CN112888430A (zh) | 2021-06-01 |
| BR112021007019A2 (pt) | 2021-07-13 |
| IL282311A (en) | 2021-05-31 |
| SG11202103588WA (en) | 2021-05-28 |
| CR20210514A (es) | 2021-11-12 |
| PE20211199A1 (es) | 2021-07-01 |
| AU2023200917A1 (en) | 2023-03-23 |
| WO2020081461A1 (en) | 2020-04-23 |
| KR20240119194A (ko) | 2024-08-06 |
| MX2021004207A (es) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| CL2018000818A1 (es) | Composición de oligonucleotidos; métodos para alterar el empalme de un transcripto blanco; y uso de la composición para tratar distrofia muscular de duchenne. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| BR112019004540A2 (pt) | método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| CL2022001079A1 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| AR122344A1 (es) | Uso de reboxetina para tratar desórdenes del sistema nervioso | |
| UY39257A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
| CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| PE20230181A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| BR112018014771A2 (pt) | composição compreendendo extrato de proteoglicanos de algas e seu uso | |
| AR112535A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria |